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POLYMER-COATED THERAPEUTIC 
NANOPARTICLES 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
0001. This application claims priority to U.S. Provisional 
Application Ser. No. 62/178,647 entitled “POLYMERIC 
NANOPARTICLES FOR DRUG DELIVERY AND BAC 
TERIAL TOXIN REMOVAL.” filed Apr. 15, 2015, the 
disclosure of which is hereby incorporated by reference as if 
set forth in its entirety herein. 
FIELD 
0002 Therapeutic agents and methods of making and 
using the same are provided. 
BACKGROUND 
0003. While there are a number of effective therapeutic 
compounds for the treatment of a number of diseases, such 
as cancer, there are some challenges to effectively delivering 
Such therapeutic compounds to the intended target site. 
Certain current drug delivery methods and systems can 
result in the degradation of the therapeutic compound prior 
to its arrival at the target site. Further, simply increasing the 
dosage to deliver an effective amount of the therapeutic 
agent to the target site may not be possible, as in certain 
scenarios, such dosages may be toxic or cause other delete 
rious side effects. 
SUMMARY 
0004. In one aspect, a polymer-coated therapeutic nano 
particle is provided. The polymer-coated therapeutic nano 
particle includes an inner core including at least one thera 
peutic agent. The inner core has a maximum dimension of 
300 nm or less. The polymer-coated therapeutic nanoparticle 
also includes an outer polymeric coating that coats at least 
a portion of the inner core, wherein the outer polymeric 
coating has a thickness of 1 nm to 100 nm. 
0005. In another aspect, a method for producing a poly 
mer-coated therapeutic nanoparticle is provided. The 
method includes forming an inner core including at least one 
therapeutic agent. The inner core has a maximum dimension 
of 300 nm or less. The method also includes coating, at least 
partly, the inner core with a layer of a bio-responsive 
polymer. The layer of the bio-responsive polymer has a 
thickness of 1 nm to 100 nm. The method further includes 
attaching at least one targeting molecule to the layer of the 
bio-responsive polymer. 
0006. In yet another aspect, a polymer-coated therapeutic 
nanoparticle. The polymer-coated therapeutic nanoparticle 
includes a rod-shaped inner core. The rod-shaped inner core 
includes an anti-cancer therapeutic agent. The rod-shaped 
inner core has a maximum dimension of 450 nm or less. The 
polymer-coated therapeutic nanoparticle also includes an 
outer polymeric coating at least partly covering the rod 
shaped inner core. The outer polymeric coating has a thick 
ness from 1 nm to 100 nm. The outer polymeric coating 
includes a bio-responsive polymer. The polymer-coated 
therapeutic nanoparticle also includes at least one targeting 
molecule covalently attached to the outer polymeric coating, 
wherein the at least one targeting molecule comprises a 
polypeptide. 
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BRIEF DESCRIPTION OF THE SEVERAL 
VIEWS OF THE DRAWINGS 
0007. The present invention is described in detail below 
with reference to the attached drawing figures, wherein: 
0008 FIG. 1 is a cross-sectional schematic view of a 
polymer-coated therapeutic nanoparticle, according to an 
aspect of the invention; 
0009 FIG. 2 is a schematic representation of a conjuga 
tion reaction for covalently attaching a targeting molecule to 
a polymer in the outer polymeric coating of a polymer 
coated therapeutic nanoparticle, according to an aspect of 
the invention; 
0010 FIG. 3 is a perspective view of an exemplary 
Solvent diffusion system for making polymer-coated thera 
peutic nanoparticles, according to an aspect of the invention; 
0011 FIG. 4 is a calibration curve for the concentration 
of camptothecin (CPT) at various absorbance values at 366 
nm, according to an aspect of the invention; 
0012 FIG. 5A is a transmission electron microscopy (TEM) image of a sample of polymer-coated therapeutic 
nanoparticles that were produced as described in Example 1, 
according to an aspect of the invention; 
(0013 FIG. 5B is a close-up TEM image of a sample of 
polymer-coated therapeutic nanoparticles that were pro 
duced as described in Example 1, according to an aspect of 
the invention; 
0014 FIG. 6A is a Zeta potential distribution curve for 
CPT nanoparticles without a PCL polymer coating, as 
described in Example 2, in accordance with an aspect of the 
invention; 
(0015 FIG. 6B is a Zeta potential distribution curve for 
PCL polymer-coated CPT nanoparticles, as described in 
Example 2, in accordance with an aspect of the invention; 
0016 FIG. 7 is the FT-IR spectra showing the degrada 
tion of functional groups of the PCL polymeric coating on 
PCL polymer-coated CPT nanoparticles as described in 
Example 3, according to an aspect of the invention; 
0017 FIG. 8A is a graph showing the percent release of 
the CPT therapeutic agent from PCL polymer-coated CPT 
nanoparticles at a pH of 6.0 as described in Example 4. 
according to an aspect of the invention; 
0018 FIG. 8B is a graph showing the percent release of 
the CPT therapeutic agent from PCL polymer-coated CPT 
nanoparticles at a pH of 6.5 as described in Example 4. 
according to an aspect of the invention; 
0019 FIG. 8C is a graph showing the percent release of 
the CPT therapeutic agent from PCL polymer-coated CPT 
nanoparticles at a pH of 7.4 as described in Example 4. 
according to an aspect of the invention; 
(0020 FIG. 9 is a plot of the 
vs. log t to describe the drug release behavior of the PCL 
polymer-coated CPT nanoparticles as described in Example 
4, according to an aspect of the invention; 
(0021 FIG. 10 is a growth inhibition curve of HER-2 
positive tumor cells in response to various concentrations of 
PCL polymer-coated CPT nanoparticles conjugated with a 
TTZ antibody or with BSA as described in Example 5, in 
accordance with an aspect of the invention; 
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0022 FIG. 11 is a growth inhibition curve of HER-2 
negative tumor cells in response to various concentrations of 
PCL polymer-coated CPT nanoparticles conjugated with a 
TTZ antibody or with BSA as described in Example 5, in 
accordance with an aspect of the invention; and 
0023 FIG. 12 is a schematic depiction of a FRET-based 
system for the detection of cancer DNA, according to an 
aspect of the invention. 
DETAILED DESCRIPTION 
0024. In various aspects, polymer-coated therapeutic 
nanoparticles are disclosed. In certain aspects, the polymer 
coated therapeutic nanoparticles can include one or more 
therapeutic agents at least partly covered with an outer 
polymeric coating. In various aspects, one or more targeting 
molecules can be associated with the outer polymeric coat 
ing in order to target the therapeutic nanoparticle to a 
particular site, Such as a tumor or another particular type of 
cell. 
0025. Formulating active therapeutic agents for targeted 
delivery and effective drug release at the target site remains 
one of the top challenges for effective treatments of various 
illnesses or diseases. In certain scenarios, an active agent in 
a therapeutic formulation may undergo modification when 
administered and be eliminated prior to the active agent 
reaching a target site, e.g., a tumor or organ. One exemplary 
active agent where such problems can occur is the anti 
cancer chemotherapy drug camptothecin (CPT). CPT has a 
lactone ring that gets converted to a carboxylate at a physi 
ological pH of 7.4. Once the lactone ring in CPT is con 
verted to a carboxylate, its affinity to human serum albumin 
(HAS) is increased and preferably becomes bound to HAS. 
which promotes the elimination of CPT from the body, prior 
to it having a chance to reach a target tumor site, thereby 
reducing the efficacy and bioavailability of the active ingre 
dient therapeutic agent (CPT). Because of this rapid elimi 
nation, it becomes necessary to increase the therapeutic 
agent, which in turn increases the toxicity of this chemo 
therapy. 
0026 Certain current strategies or methods have been 
utilized to prevent the conversion and/or degradation of an 
active agent, such as CPT. However, some of these CPT 
formulations have been known to cause hepatic toxicity and 
renal failure, and/or tend to aggregate, which reduces their 
bioavailability. 
0027. The polymer-coated therapeutic nanoparticles 
described herein address one or more of the problems 
mentioned above. In certain aspects, the polymer-coated 
therapeutic nanoparticles can effectively protect an active 
therapeutic agent while that agent is specifically delivered to 
a target site. In such aspects, the polymer-coated therapeutic 
nanoparticles can include an outer polymeric coating includ 
ing one or more biodegradable or bio-responsive polymers 
that can prevent the premature degradation and/or modifi 
cation of the therapeutic active agent once administered to a 
patient. Further, in Such aspects, one or more targeting 
molecules can be associated with the outer polymeric coat 
ing to target the therapeutic active agent to a particular target 
site. Such as a tumor. In certain aspects, the outer polymeric 
coating can maintain at least partially intact under general 
physiological conditions (e.g., pH 7.4), and may at least 
partially degrade in the local physiological conditions asso 
ciated with a tumor (e.g., a lower pH of about 6.0 to about 
6.5). In such aspects, the polymer-coated therapeutic nano 
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particles may stay coated and protected from degradation 
until it reaches its target site. Such as tumor, at which time 
the outer polymeric coating can be degraded thereby releas 
ing the inner therapeutic active agent. Further, in various 
aspects, the polymer-coated therapeutic nanoparticle may be 
rod-shaped to allow for increased cellular uptake and/or 
reduced phagocytosis, both of which may increase the 
effectiveness of the therapeutic agent. 
0028. In certain aspects, an elongated rod-shaped design 
of the polymer-coated therapeutic nanoparticles allows for 
long circulation time in the body, and multivalent interac 
tions with target cells, such as tumor cells, increasing the 
probability of receptor-ligand interactions. In Such aspects, 
due to the fluid dynamics induced by the unique rod shape, 
the nanoparticles can flow along the edges of blood vessels. 
By flowing along the sides of blood vessels, nanoparticles 
may reach the target cells, e.g., tumor or cancer cells, due to 
the gaps in the endothelial cell wall between the tumorous 
tissue and the blood vessels. 
0029. Furthermore, as discussed above, the microenvi 
ronment of tumorous tissue can be slightly more acidic with 
a pH of about 6-6.5, as compared to the pH of blood, which 
has a pH of about 7.4. This discrepancy in pH may be 
advantageously used in accordance with aspects of the 
present invention where the outer polymer coating may be 
selected to be resistant to degradation at pH 7.4, but quickly 
degrades at the more acidic pH of the tumorous tissue, 
thereby effectively releasing the therapeutic agent at the 
desired site of action. Thus, in certain aspects, the polymer 
coated therapeutic nanoparticles can be customized taking 
into consideration the target microenvironment to increase 
the efficacy of the therapeutic agent by several fold, while at 
the same time reducing the side effects of the therapeutic 
agent because effective concentrations of the therapeutic 
agent can be delivered to target sites at lower doses. 
0030 FIG. 1 is a schematic view of one aspect of a 
polymer-coated therapeutic nanoparticle 100. The polymer 
coated therapeutic nanoparticle 100 of FIG. 1 includes an 
inner core 102, an outer polymeric coating 104, and one or 
more targeting molecules 106. The inner core 102 can 
include one or more therapeutic agents. In certain aspects, 
the therapeutic agent can include any pharmaceutical. In one 
or more aspects, the therapeutic agent can include an anti 
cancer agent, such as CPT. 
0031. In certain aspects, the inner core 102 can include at 
least about 20 wt.%, at least about 40 wt.%, at least about 
50 wt.%, at least about 60 wt.%, at least about 70 wt.%, 
at least about 80 wt.%, at least about 90 wt.%, at least about 
95 wt.%, at least about 99 wt.%, or about 100 wt.% 
therapeutic agent relative to the weight of the inner core 102. 
In certain aspects, the therapeutic agent may be present in 
high concentrations in the inner core 102 at least partly 
because the outer polymeric coating 104 can encapsulate 
and protect the inner core 102 comprising the therapeutic 
agent, thereby minimizing or eliminating the need for 
excipients in the formulation of the therapeutic agent, Such 
as fillers and Stabilizers, depending on the specific chemistry 
of the therapeutic agent. 
0032. In aspects where the inner core 102 include less 
than about 100 wt.% therapeutic agent, the remainder can 
include one or more pharmaceutically acceptable excipients. 
In various aspects, one or more pharmaceutically acceptable 
excipients can be present in the inner core 102 in an amount 
of at least about 0.01 wt.%, at least about 0.1 wt.%, at least 
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about 1 wt.%, at least about 5 wt.%, or at least about 10 wt. 
%, and/or less than about 50 wt.%, less than about 40 wt. 
%, less than about 30 wt.%, less than about 20 wt.%, or less 
than about 15 wt.% relative to the weight of the inner core 
102. It is appreciated that pharmaceutically acceptable 
excipients are commercially available and can be chosen by 
one skilled in art for a specific purpose. Examples of Such 
excipients can be found, for example, in the Handbook of 
Pharmaceutical Excipients, 7" ed., 2012, Pharmaceutical 
Press, incorporated herein by reference. 
0033. In various aspects, the inner core 102 can be 
rod-shaped. As used herein, a rod-shaped inner core refers to 
the inner core having an elongated cylindrical (where the 
length 1 is greater than the diameter d) or rectangular shape 
(where the length 1 is greater than the width w). In certain 
aspects, the entire polymer-coated therapeutic nanoparticle 
100 can be rod-shaped. 
0034. In certain aspects, the inner core 102 can have a 
length or maximum dimension of about 450 nm or less, 
about 400 nm or less, about 350 nm or less, about 300 nm. 
or less, about 250 nm or less, about 200 nm or less, or, 
between about 150 nm and about 200 nm, between about 
100 nm and about 400 nm, between about 150 and about 300 
nm, between about 50 nm and about 300 nm, between about 
10 nm and about 400 nm, or between about 10 nm and about 
200 nm. As used herein, maximum dimension of the inner 
core 102 refers to the largest dimension of the inner core 
102. For example, for a rod-shaped inner core, the maximum 
dimension refers to the largest of the length and diameter if 
the inner core is an elongated cylindrical shape, or the largest 
of the length, width, and depth of the rod-shaped inner core 
if the inner core is rectangular shaped. 
0035. In one or more aspects, the outer polymeric coating 
104 can include one or more polymers. In various aspects, 
the polymers used in the outer polymeric coating 104 should 
be non-toxic so that they can be administered to a patient. In 
certain aspects, the polymer can be a biodegradable and/or 
bio-responsive polymer. As used herein, a bio-responsive 
polymer refers to a polymer that is capable of at least partly 
being chemically broken down when exposed to a particular 
physiological environment. For example, as discussed in 
detail below, poly(e-caprolactone) (PCL) can be at least 
partly chemically degraded at a pH of about 6, but not at all 
(or less so) at pH 7.4. In this example, PCL would not be 
substantially degraded in the blood (approximately a pH of 
7.4) but would be at least partly degraded at a lower pH of 
about 6 (approximately the pH associated with a tumor 
microenvironment). In certain aspects, a biodegradable 
polymer can be a polymer that is capable of at least being 
partially chemically broken down in a particular biological 
environment, such as via bacteria or the like. 
0036. In certain aspects, the outer polymeric coating 104 
can include poly(e-caprolactone) (PCL), polylactic acid 
(PLA), Poly(lactic-co-glycolic acid (PLGA), hyaluronic 
acid (HA), poly(acrylic acid) (PAA), poloxamers, polyeth 
ylene oxide (PEO), polyethylene glycol (PEG), polyflutamic 
acid, or a mixture thereof. It is appreciated that one skilled 
in the art would understand that other polymers or other 
materials could be used for the outer polymeric coating 104 
as long as Such materials are non-toxic in the sense that they 
can be administered to a patient as a coating for at least one 
therapeutic agent. 
0037. As can be seen in FIG. 1, the outer polymeric 
coating 104 entirely encapsulates the inner core 102. In 
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alternative aspects, the outer polymeric coating 104 may 
partly encapsulate the inner core 102. 
0038. In certain aspects, the outer polymeric coating 104 
can have a maximum thickness t of about 150 nm or less, 
about 100 nm or less, about 80 nm or less, about 50 nm or 
less, about 30 nm or less, about 10 nm or less, or between 
1 nm and 100 nm, between 1 and 50 nm, or between 5 and 
70 nm. 
0039. As can be seen in FIG. 1, the outer polymeric 
coating 104 is a Substantially even coating, meaning that it 
has Substantially the same thickness throughout the coating. 
In certain aspects not depicted in the figures, the outer 
polymeric coating may vary in thickness; yet, the maximum 
thickness of the coating in this instance can be within the 
maximum thickness parameters immediately described 
above. 
0040. As discussed above, in various aspects, one or 
more targeting molecules 106 may be associated with the 
outer polymeric coating 104. In such aspects, the targeting 
molecules 106 can facilitate the targeted delivery of the 
therapeutic agent to a specific target site, such as a tumor. In 
certain aspects, the targeting molecule can include one or 
more antibodies or fragments of antibodies, or other poly 
peptides. In certain aspects, the fragments of one or more 
antibodies include the antigen binding region commonly 
known as the fragment antigen binding (Fab) fragment. In 
Such aspects, the Fab fragment may be formed by enzymatic 
digestion of a full length antibody. In alternative aspects, the 
targeting molecule can include molecules other than pro 
teins, such as synthetic or natural receptor ligands. 
0041. In certain aspects, the antibodies, polypeptides, or 
other targeting molecules may be selected to be specific to 
the type of cells to be treated by, for example, matching the 
antibodies or polypeptides to receptors overexpressed in 
cancerous tissues such as human epidermal growth factor 
receptor 2 (HER-2) in breast cancer, or G-protein-coupled 
receptors (GPCRs), which has been linked to cancers such 
as melanoma, lymphoma, lung cancer, gastric cancer, etc. 
Thus, in Such aspects, the targeting molecule will work to 
increase the concentration of the polymer-coated therapeutic 
nanoparticle at the tumor site and release the therapeutic 
agent in the inner core at the tumor site due to the degra 
dation of the outer polymeric coating in the tumorous tissue 
microenvironment, e.g., due to the lower pH of this microen 
Vironment. 
0042. In certain aspects, the targeting molecule may be 
covalently attached to the outer polymeric coating. For 
example in Such aspects, an ester functional group in a 
portion of a polymer in the outer polymeric coating can react 
with an available amine functional group of a polypeptide or 
antibody target molecule to form an amide bond thereby 
covalently attaching the target molecule to the outer poly 
meric coating and to the polymer-coated therapeutic nano 
particles. FIG. 2 provides one example of a target molecule 
conjugated to the outer polymeric coating via an amide 
bond. In the example of FIG. 2, an ester group of the PCL 
polymer, e.g., in the outer polymeric coating, can react with 
an amine group on the Herceptin (Trastuzumab) monoclonal 
antibody to form an amide bond covalently attaching the 
Herceptin antibody to the outer polymeric coating. In the 
example of FIG. 2, the ester group of the polymer and the 
amine group of the targeting molecule are not sterically 
hindered, which allows for this covalent attachment while 
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avoiding any preliminary modifications of the antibody or 
polypeptide, which may reduce the activity of the antibody 
or polypeptide. 
0043. While an ester functional group of an exemplary 
polymer is used in the above example to illustrate the 
covalent attachment of the targeting molecule to the outer 
polymeric coating, it is appreciated that other functional 
groups (such as a carboxylic acid functional group) in a 
polymer used in the outer polymeric coating can be used to 
provide for a covalent attachment to a targeting molecule. 
Further, it is appreciated that one skilled in the art would be 
able to modify a portion of a polymer in the outer polymeric 
coating in order to provide for a covalent attachment 
between the polymer in the outer polymeric coating and a 
targeting molecule, for example, by converting a portion of 
the polymer to a carboxylic acid or ester functional group. 
0044 As discussed above, in certain aspects a method of 
producing the polymer-coated therapeutic nanoparticles is 
provided. In certain aspects, a solvent diffusion method can 
be utilized to form the polymer-coated therapeutic nanopar 
ticles. In the solvent diffusion method, a therapeutic agent in 
an organic solvent, such as dimethylsulfoxide (DMSO), and 
a polymer for the outer polymeric coating in an organic 
Solvent, Such as toluene, are separately injected, e.g., via a 
Syringe pump, into an aqueous solution, e.g., water. The 
therapeutic agent Solution and the polymer Solution can be 
injected into the aqueous solution simultaneously or sequen 
tially. In one aspect, the therapeutic agent solution and the 
polymer solution are be injected into the aqueous solution 
simultaneously. Without being bound by any particular 
theories, it is believed that when the therapeutic agent 
Solution is injected into the aqueous solution, an inner core 
nanoparticle of the therapeutic agent is formed because of 
the phase separation from the DMSO oil phase into the water 
(or aqueous Solution) under mild stirring. Further, without 
being bound by any particular theory, it is believed that at the 
same time that the inner core is formed, a continuous or 
semi-continuous polymer film coats the inner core by virtue 
of van der Waals attractive forces between the inner core 
particle Surface and the polymer under low shear stress, and 
it is also believe that the combination of adhesive and shear 
forces spread the polymer thinly over each inner core 
particle. The dispersion may be stirred continuously for an 
extended period of time to remove any residual organic 
Solvent by evaporation. After the residual organic solvent is 
removed by evaporation, the polymer-containing therapeutic 
nanoparticles may then be separated from the aqueous phase 
by centrifugation, repeating this step as necessary with 
added water, for washing the nanoparticles from any 
residual organic solvents. Then, the polymer-containing 
therapeutic nanoparticles may be lyophilized, weighed, and 
stored at a temperature of about 4°C. It is appreciated that 
one skilled in the art understands that the concentration of 
polymer(s) in the organic solvent, the concentration of the 
therapeutic agent in an organic solvent, the injection rate of 
the polymer Solution and/or the therapeutic agent Solution 
into the aqueous solution, and/or the particular components 
of the aqueous solution can be modified to achieve specific 
sized and shaped nanoparticles. 
0045. In certain aspects, the concentration of polymer in 
the organic solvent or the therapeutic agent in the organic 
solvent can range from about 0.1 mg/mL to about 1000 
mg/mL, or from about 1 mg/mL to about 100, or can be at 
least about 0.1 mg/mL, or at least about 1 mg/mL. In certain 
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aspects, the concentration of polymer in an organic solvent 
can be about 1 mg/mL and the concentration of the thera 
peutic agent in an organic solvent can be about 10 mg/mL. 
In one or more aspects, the flow rate or injection rate of the 
organic solvent comprising one or more polymers into the 
aqueous phase can range from about 0-1000 uL/sec. Further, 
in certain aspects, the flow rate or injection rate of the 
organic solvent comprising the therapeutic agent into the 
aqueous phase can range from about 0-1000 LL/sec. 
0046 FIG.3 depicts an exemplary system 300 that can be 
utilized to synthesize polymer coated therapeutic nanopar 
ticles using a solvent diffusion method. The system 300 can 
include a syringe pump 302 for injecting the polymer 
containing Solution via line 304 and the therapeutic agent 
containing solution via line 306 into an aqueous solution 310 
housed in a vessel 308. A homogenizer 312 can also be 
positioned inside the vessel 308. It is appreciated that the 
components of this system 300 are commercially available 
and known to one skilled in the art. 
0047. In various aspects, the solvent diffusion method 
described above can result in the formation of a plurality of 
polymer-coated therapeutic nanoparticles. In certain aspects, 
the polymer-coated therapeutic nanoparticles can have a 
Substantially uniform size. In alternative aspects, the poly 
mer-coated therapeutic nanoparticles can have different 
sizes. In one or more aspects, the polymer-coated therapeu 
tic nanoparticles can have a polydispersity index value of 
about 0.05, 0.1, 0.2,0.3, or 0.4. 
0048. In certain aspects, methods for treating a patient are 
provided. In Such aspects, these methods can include admin 
istering a patient a therapeutically effective amount of 
polymer-coated therapeutic nanoparticles. In certain aspects, 
a therapeutically effective amount can be an amount Sufi 
cient to provide a biologically beneficial effect to the subject 
Such as by producing a beneficial change in a disease state 
or inhibiting the progression of a disease, such as preventing 
or reducing tumor growth or cancer cell growth. 
0049. In certain aspects, the polymer-coated therapeutic 
nanoparticles can be administered to a subject using any 
conventional routes of administration known to one skilled 
in the art. A non-limiting list of Such routes includes admin 
istration intravenously, Subcutaneously, by pill, topically, 
and local administration. 
0050. In one or more aspects, prior to administration, the 
polymer-coated therapeutic nanoparticles may be mixed 
with one or more inactive ingredients, such as solvents, 
diluents, additives, pharmaceutically acceptable excipients, 
enhancers, pharmaceutically acceptable carriers, and com 
binations thereof. It is appreciated that Such inactive ingre 
dients may be chosen by one skilled in the art for a particular 
route of administration and other common considerations. 
AS Such, such administration formulations and components 
will not be further described herein. 
EXAMPLES 
Polymer-Coated Therapeutic Nanoparticles 
0051. The concepts discussed herein will be further 
described in the following examples, which do not limit the 
Scope of the various aspects described in the claims. 
0.052 Each experiment in the below examples that 
included quantified measurements was carried out in at least 
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three independent experiments with triplicate measure 
ments. Data were Summarized using means and standard 
deviations. 
Example 1 
Synthesis of PCL Polymer-Coated Camptothecin 
(CPT) Therapeutic Nanoparticles 
0053 All reagents were purchased from Sigma-Aldrich 
unless otherwise specified. A thin layer of continuous PCL 
polymer (14,000 Da) film was deposited on inner core CPT 
nanoparticles using the solvent diffusion method. Specifi 
cally, 1 mL each of 10 mg/mL of CPT in DMSO and 1 
mg/mL of PCL polymer in toluene were added to 20 ml of 
reverse osmosis (RO) water using a syringe pump, Such as 
the syringe pump 302 discussed above with reference to 
FIG. 3. Residual toluene was removed by stirring (300 rpm) 
the CPT-PCL nanoparticle suspension overnight at room 
temperature (-22°C.). DMSO was removed by centrifuga 
tion at 3,000 rcf, followed by five times washing using RO 
water. PCL-coated CPT (CPT-PCL) nanoparticles were 
freeze-dried, weighed and stored at 4° C. CPT concentra 
tions were measured, and quantified by reading absorbance 
at 366 nm using a plate reader (BioTek Synergy), and the 
CPT calibration curve shown in FIG. 4. The theoretical 
content of the PCL polymer weight in the CPT-PCL nano 
particles was calculated based on the weight of freeze-dried 
particles and CPT amount. The dry w:w ratio of CPT:PCL 
was 0.03. 
Example 2 
Characterization of CPT-PCL Nanoparticles 
0054 The morphology and size of CPT-PCL nanopar 
ticles produced in Example 1 were examined under trans 
mission electron microscope (TEM) (Tecnai F20) at an 
accelerating voltage of 120 kV. A drop of 10 ul CPT-PCL 
nanoparticle solution in water was air-dried on carbon 
coated copper grids (Tedpella). The CPT-PCL nanoparticle 
diameter, CPT-PCL nanoparticle length, and thickness of the 
PCL outer polymeric coating were measured using Image.J 
(version 1.45S, NIH, USA) for at least 20 CPT-PCL nano 
particles. FIGS. 5A and 5B show representative TEM 
images. As can be seen in FIGS. 5A and 5B the polymer 
coated therapeutic nanoparticles have a rod-shape. These 
rod-shaped CPT-PCL nanoparticles had a length or maxi 
mum dimension of 500.9 nmit91.3 nm and a width or 
diameter of 122.7 nmit 10.1 nm. Further, based on these 
TEM images, the PCL coating thickness was determined to 
be 10.3-1.4 nm. This is a soft coating technique that does 
not require high mechanical agitation, Sonication or vibra 
tion, thus preventing any structural damage of therapeutic 
agents in the inner core. 
0055. The surface charges of the CPT-PCL nanoparticles 
in PBS were determined by dynamic light scattering (DLS) 
using a NanoSeries Zetasizer ZS 90 (Malvern) and the 
backscattering detection at 90°. The Zeta potential was 
measured for the CPT-PCL nanoparticles for 15 runs. For 
comparison, the Zeta potential was also measured for CPT 
nanoparticles lacking the PCL polymer coating. Data was 
analyzed using means and standard deviations of three 
concentrations. The results are shown in FIGS. 6A and 6B 
for the CPT nanoparticles alone in and the CPT-PCL nano 
particles, respectively. Both samples were in phosphate 
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buffered saline (PBS). The Zeta potential of the CPT nano 
particles alone was -26.8+7.71 mV, while the Zeta potential 
of the CPT-PCL nanoparticles was -15.5+3 mV. An increase 
in Zeta potential for the CPT-PCL nanoparticles indicates the 
deposition of the PCL polymer on the surface of CPT inner 
core particles. 
Example 3 
Degradation of the PCL Coating on the CPT-PCL 
Nanoparticles 
0056. The degradation of the PCL coating of the CPT 
PCL nanoparticles made in Example 1 was analyzed by 
Fourier transform infrared spectroscopy “FT-IR spectros 
copy.” The disappearance of ester groups in the PCL back 
bone, and appearance of carboxyl and hydroxyl groups were 
studied using FT-IR spectra. CPT-PCL nanoparticles were 
incubated for 72 hours at 37° C. in PBS at pH 6 (which 
mimics the slightly acidic cancer microenvironment). 
Samples were freeze-dried to sublimate any water, and 
ground at a 1:100 weight ratio with FT-IR grade potassium 
bromide (KBr; Alpha Aesar). Hydrolytic degradation was 
monitored by comparing the intensity of ester, alcohol and 
carboxyl bands at t=0 and 72 h for the same amount of PCL 
in NRs. The FT-IR absorbance spectra were obtained for 32 
scans over the range of 4000-400 cm using a Thermo 
Nicolet Nexus 470 FT-IR spectrometer. Background noises 
were subtracted from the spectra. All spectra were analyzed 
using EZ OMNIC E.S.P v.5.1 software. FIG. 7 shows the 
FT-IP spectra. 
0057 The presence of a strong band at 1728 cm' is due 
to the presence of an ester carbonyl group that corresponds 
to the CO stretching in the PCL polymer coating before 
degradation (dotted line). The band intensity decreased at 
1728 cm after 72 h due to hydrolytic cleavage of ester 
bonds at pH 6 (solid line). The peak at 1288 cm represents 
C C and C=0 stretching in the PCL polymer backbone. 
The peaks at 2860 and 2931 cm correspond to the char 
acteristic absorption of the C-H stretching bonds of e-CL. 
The appearance of two peaks at 1652 cm and 3440 cm 
indicate the presence of carboxyl ( COOH) and hydroxyl 
(—OH) groups, respectively. These peaks represent the 
hydrolysis of ester bonds, forming a carboxylic acid group 
and an organic alcohol. The -OH group attributes to the 
formation of alcohol group as well as the OH group of 
lactone ring of CPT, indicating the retention of the active 
ring of CPT. 
Example 4 
Quantification of CPT Drug Release from the 
CPT-PCL Nanoparticles 
0.058 CPT drug release was monitored by exposing CPT 
PCL nanoparticles to phosphate buffered saline (PBS) at pH 
6 or pH 6.5 (to mimic the cancer microenvironment), or at 
pH 7.4 (to mimic the pH of blood) and at 37° C. without 
stirring. 500 ul of the PBS buffer were sampled at different 
time intervals oft–0, 0.5, 2, 4, 8, 24, 36 and 72 h. CPT drug 
concentrations that were released to the buffer were mea 
sured using absorbance at 366 nm and a CPT standard curve 
(shown in FIG. 4). FIGS. 8A, 8B, and 8C show the % CPT 
released over time at a pH of 6.0, 6.5, and 7.4, respectively. 
As can be seen in FIGS. 8A, 8B, and 8C the degradation of 
the PCL coating as evidenced by the CPT release is signifi 
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cantly faster from the 2 hour to 24 hour time period for the 
CPT-PCL nanoparticles in PBS solutions at a pH of 6.0 
(FIG. 8A) and 6.5 (FIG. 8B) compared to the CPT release 
over the same time period (2-24 hours) for the CPT-PCL 
nanoparticles in PBS solutions at a pH of 7.4 (FIG. 8C). 
These results show that the CPT-PCL nanoparticles release 
more CPT in a tumor microenvironment (e.g., pH 6.0 to pH 
6.5) than in the blood (e.g., pH 7.4). 
0059 Looking more closely at the data in FIG. 8A, a slow 
release was observed with 8.2% CPT release in the first 0.5 
h following 32.6% release after 8 h, and 51.5% after 72 h. 
CPT was released from the PCL-coated nanoparticles by 
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stirring to mix, and incubated the mixture at room tempera 
ture (~25°C.). Any unreacted reagents were separated using 
100 kDa membrane filters (EMD Millipore Amicon Ultra 
0.5). The supernatants were collected by centrifugation at 
1,000 rcf, and analyzed by the BCA protein assay (Pierce 
Thermo Scientific). Bovine serum albumin (BSA) was used 
to prepare HER-2 non-targeted CPT-PCL NRs as HER-2 
negative controls (TTZ binds to HER-2). TTZ covalent 
binding would help deliver the CPT-PCL nanoparticles to 
breast cancer cells. Using the BCA protein assay, it is 
calculated that the weight ratio of CPT:PCL:TTZ is 1:29:3.5 
(Table 1 below). The ratio of CPT:PCL:BSA was almost the 
same as 1:29:2.1 (Table 1). 
TABLE 1. 
Weight ratios of CPT, PCL, and TTZ 
Amount 
of CPT in TTZ in PCL in 
CPT CPTPCL- CPTPCL 
PCL-TTZ TTZ TTZ CPTPCL:TTZ 
nanoparticles, nanoparticles, nanoparticles, W.W 
19. 19. 19. Ratio 
715.44 2512.65 444.87 20824.095439.37 1:29:3.5 
18688 
hydrolytic disruption of the PCL coating and the drugs 
diffusion. The CPT drug release data were fitted to the 
following well-known power law equation (2) that describes 
the drug release behavior from polymeric systems: 





is the fraction of drug released at time t, k is the kinetic 
constant, and n is the diffusion exponent for drug release. By 
plotting 
( M., lost 
vs. log t (as shown in FIG. 9), n was calculated as 0.4 for 
CPT drug release, indicating a Fickian drug diffusion. 
Example 5 
Conjugation of an Antibody on the Surface of 
CPT-PCL Nanoparticles 
0060 Trastuzumab (TTZ) antibody (Genentech) was 
conjugated to the surface of CPT-PCL nanoparticles by 
coupling primary amines of TTZ with ester groups of PCL 
forming amide bonds. Specifically, a 10 mg/ml TTZ solution 
was prepared in PBS at pH 7.4. 10 mg of CPT-PCL 
nanoparticles were added to 1 ml of the TTZ solution, 
CPT in BSA in PCL in 
CPT- CPTPCL- CPTPCL 
PCL-BSA BSA BSA CPTPCL:BSA 
nanoparticles, nanoparticles, nanoparticles, W:W 
19. 19. 19. Ratio 
848.38 277.SS 1755.78 772.16 24693.OS 8078. SS 1:29:2.1 
Example 6 
Breast Cancer Cell Growth by CPT-PCL 
Nanoparticles Conjugated with TTZ Antibody 
0061 The effectiveness of combination treatments using 
PCL-CPT-TTZ nanoparticles were evaluated in HER-2 posi 
tive BT-474 breast cancer cells (ATCC) and HER-2 negative 
cell line MDA-MB-231 (ATCC). The cells were cultured in 
Hybri-Care (ATCC), and RPMI 1640 (Life Technologies), 
respectively supplemented with 10% FBS (Corning) and 1% 
(100 units/ml) Penicillin-Streptomycin (Gibco) at 37° C. and 
5% CO. HUVEC cells (Invitrogen) were used as a normal 
cell control that was cultured in Medium 200 (Invitrogen) 
with Low Serum Growth Supplement (LSGS) kit (Invitro 
gen). Cells were plated in 96-well tissue culture plates 
(Corning) at a density of 10,000 cells/well in 200 ul respec 
tive medium. After 18 hours of growth, 10 ul of nanopar 
ticles made in Example 5 were added to the medium. The 
final concentrations of CPT were 0.1, 0.2,0.5, 1, 2, 5 and 10 
ug/ml. The corresponding PCL concentrations were 2.9, 5.8, 
14.6, 29.1, 58.2, 145.5, and 291.1 ug/ml, respectively, and 
TTZ concentrations were 0.4, 0.8, 1.9, 3.8, 7.5, 18.8, and 
37.7 ug/ml, respectively. CPT-PCL-BSA nanoparticles made 
in Example 5 were used as a HER-2 non-specific control. 
Cells were also treated with the same concentrations of PCL 
solutions to determine its cytotoxic effects. Cells treated 
with 10 ul of PBS were used as positive controls. 3 hours 
later, the medium was replaced with fresh medium. After 72 
hours, the plates were centrifuged at 100 rcf for 15 min. The 
supernatants were discarded. Live cells were stained with 2 
uM calcein AM (Life technologies) in PBS by incubating at 
room temperature for 30 min. The fluorescence intensity 
(F.I.) of calcein AM was measured using 485/528 excitation/ 
emission filters using the plate reader (BioTek Synergy 2). 
The percentage inhibition in cell growth was calculated 
using the following equation (2): 
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% inhibitionin cell growth= (2) 
F.I. of PBS treated cells - F.I. of samples 
F.I. of PBS treated cells 
x 100 
0062. The therapeutic activity of CPT-PCL-TTZ nano 
particles was evaluated in HER-2 positive BT-474 (FIG. 10) 
and HER-2 negative MDA-MB-231 cells (FIG. 11) at vary 
ing concentrations. These are the previously reported dosage 
amounts of CPT in human breast cancer cells. The NRs 
inhibited the growth of HER-2 positive BT-474 cells in a 
dose dependent manner. The combination of CPT and TTZ 
using CPT-PCL-TTZ nanoparticles inhibited up to 61.6% 
BT-474 cell growth at 10 g/ml. At this concentration, 
CPT-PCL-TTZ nanoparticles inhibited the cell growth 1.5 
fold more than CPT-PCL-BSA nanoparticles. The difference 
in growth inhibition between CPT-PCL-TTZ nanoparticles 
and CPT-PCL-BSA nanoparticles indicates the antibody 
dependent growth inhibition effects of TTZ on HER-2 
positive BT-474 cells. Interestingly, HER-2 negative MDA 
MB-231 cell line was also sensitive to the nanoparticles. No 
difference between CPT-PCL-BSA nanoparticles and CPT 
PCL-TTZ nanoparticles was found in HER-2 negative 
MDA-MB-231 cells, indicating non-specific CPT-evoked 
growth inhibition. 
Engineering Glass Nanofibers and Fluorescent Polymers for 
Early Cancer Diagnosis 
0063. In certain aspects, systems and methods are dis 
closed that are directed to the early diagnosis of cancer using 
fluorescent polymers or fluorescent glass nanofibers. 
0064. Finding early relevant cancer in people with no 
symptoms, as opposed to diagnosing the disease in its 
advanced stage, can be an important part of diagnosing and 
treating cancer patients. We have aimed to design an imag 
ing agent using a conjugate of fluorescent glass nanofibers 
(such as those that are commercially available, e.g., from the 
MO-SCI Corporation) or fluorescent polymers and DNA 
staining organic dyes for detecting any alterations in normal 
DNA into a tumor DNA. The common characteristics of 
DNA deregulation are going to be stored in a computational 
database to generate information on Suspected DNA allow 
ing intervention of cancer prior to its progression and 
implementation into clinical applications as a non-invasive 
method. FIG. 11 illustrates a flow 1100 of a hypothesis on 
FRET-based detection of cancer DNA using a conventional 
nucleic acid stain (NAS) as FRET acceptor and GNF as 
FRET donor. The GNF-NAS conjugates will display pho 
to stable fluorescence emission to image the chromatin of the 
nucleus to detect any abnormalities in DNA. Diagnosing and 
monitoring cancers have been developed extensively during 
the last two decades to detect cancer cells early. However, 
most of the approaches diagnose the disease at the advanced 
stage when the biomarkers are overexpressed on cancer 
cells, or circulated in the patient’s blood. In addition, the 
existing methods require cumbersome and time consuming 
experiments to isolate, process and analyze the samples. 
0065. As discussed further herein, a fluorescence reso 
nance energy transfer (FRET) based nuclear sensor for the 
early detection of cancer cells has been developed by 
imaging and analyzing the structural alterations e.g., mor 
phology, shape, size and nuclear matrix of the cell nuclei 
more easily. A comprehensive computational database on 
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the pattern of DNA malfunction is going to be used to track 
any symptoms of a healthy versus risky nucleus at an early 
Stage. 
0.066 For background purposes, early detection of cancer 
can decrease the mortality rate of some major cancers. There 
are a variety of Screening tests such as body fluid (blood, 
urine, saliva etc.) biomarker tests, circulating tumor cell 
identification, cell free nucleic acid (NA) detection and 
breathing tests among others for early cancer detection. 
Nanoparticles (NPs) have also been used for the detection of 
biomarkers. However, current systems suffer from false 
positive or negative results, and are limited only for aggres 
sive cancers and not applicable to detect cancer at the early 
stage. Alterations in NAS are common characteristics of 
tumor progression, and can be used for diagnosis. However, 
no such NPs have been developed to characterize the nuclei 
in cancer phenotypes. Here, we propose to synthesize a 
FRET-based conjugate using fluorescent glass nanofibers 
(such as those that are commercially available, e.g., from the 
MO-SCI Corporation) or fluorescent polymers as donors, 
and NA staining organic dyes such as propidium iodide (PI) 
or SYTO stain as acceptors. 
0067 Recently, fluorescent glass nanofibers (GNFs) 
(www.mo-sci.com/identisphere) and fluorescent polymers 
have emerged as biomarkers. The spectral overlap of emis 
sion of GNFs with the absorption wavelength of nuclear dye 
acceptor gives a favorable condition for FRET from GNFs 
to nucleic acid stain (NAS)s (see e.g., FIG. 12). When the 
FRET donor and acceptor molecules are brought in close 
proximity (~1-10 nm) to each other, in this project the GNF 
and NAS, respectively, energy transfers from GNF (donor) 
to NAS (acceptor) upon excitation at GNF’s excitation 
wavelength resulting in fluorescence emission of NASS at 
longer wavelengths. 
0068 Preliminary studies have been performed that dem 
onstrate the feasibility of the proposed studies. Some of our 
findings were as follows. The nuclei of prostate cancer cells 
were imaged under confocal fluorescence microscopy show 
ing irregular shaped hetreochromatin with dispersed aggre 
gates. The nuclear membrane as stained by the lamin anti 
body showed folded, discrete and inhomogeneous nuclear 
membrane. Detailed structures of the cancer cell nucleus 
were required to describe these abnormalities. 
0069. A novel, sensitive NA staining probe has been 
developed by conjugating GNFs with organic NASs, as 
shown in FIG. 11. Additionally, new analytical methods 
have been developed to readout descriptive statistics of 
nuclear size, shape, chromatin distribution and abnormal 
textures of chromatin. It is noted that while fluorescent glass 
nanofibers are described herein, fluorescent polymers. Such 
as those that are commercially available, may also be used 
in conjunction with the methods and systems herein. 
Example A 
Synthesis of GNF and NAS Conjugates 
(0070 GNFs will be conjugated with DNA binding mol 
ecules using activated carboxyl groups on GNFS and amines 
on NAS by EDC/NHS chemistry. The emission of GNFs at 
the excitation range of NASS will serve as an appropriate 
FRET donor, and thus can create stable fluorescent signals 
of NAS. Light spectroscopy and fluorescence will be quan 
tified for both GNFs and NASs by measuring their absor 
bance, excitation and emission spectra using a confocal 
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microscope and single cell imaging system. FRET efficiency 
will be measured using the fluorescence intensity of GNF in 
presence and absence of NAS. The size and shape of the 
particles will be determined using dynamic light scatter and 
SEM. 
Example B 
Fluorescence Imaging and Quantification Using 
Image.J. Analysis 
0071. The nuclear architectures of cancer cells are sig 
nificantly different than normal cells. The nuclear changes in 
cancer cells include irregular shape, abnormal folds inside 
nuclear membrane, coarse heterochromatin aggregates and 
abnormal nucleoli. Imaging cellular nucleus using a fluo 
rescent GNF probe, therefore, is highly desirable to specu 
late on the possible correlations between nuclear changes 
and cancer progression. Fluorescence confocal microscopy, 
single cell imaging and image analysis systems will be used 
to analyze GNF conjugated NAS. Various cancers including 
breast, prostate, colon and lung cancers and normal cell lines 
will be incubated with particles to image the cell nuclei. 
Image.J Software will be used to quantitatively measure 
nuclear architecture Such as size, shape and number of 
chromosomes. The average nuclear size will be calculated 
for ~50 nuclei for each sample of normal versus cancer cells 
to identify the development of cancer. A percentage devia 
tion of 10-20% will be considered as a cancer threshold. A 
database will be developed defining the area, volume, 
nuclear boundary, and chromatin texture features from the 
statistical analysis of the fluorescence levels of the micro 
scopic images. In vivo fluorescence imaging will be accom 
plished in the future after establishing the in vitro model. 
This method will speed up the early diagnosis of cancer 
leading to a greater chance of Survival for any patients with 
defective chromosomal diseases at a fraction of the cost of 
commonly used imaging studies. 
0072 From the foregoing, it will be seen that this inven 
tion is one well adapted to attain all the ends and objects 
hereinabove set forth together with other advantages which 
are inherent to the systems and methods. 
0073. It will be understood that certain features and 
subcombinations are of utility and may be employed without 
reference to other features and subcombinations. This is 
contemplated by and is within the scope of the claims. 
0074 Since many possible aspects may be made of the 
invention without departing from the scope thereof, it is to 
be understood that all matter herein set forth or shown in the 
accompanying drawings is to be interpreted as illustrative 
and not in a limiting sense. 
What is claimed is: 
1. A polymer-coated therapeutic nanoparticle, compris 
ing: 
an inner core comprising at least one therapeutic agent, 
wherein the inner core has a maximum dimension of 
300 nm or less; and 
an outer polymeric coating that coats at least a portion of 
the inner core, wherein the outer polymeric coating has 
a thickness of 1 nm to 100 nm. 
2. The polymer-coated therapeutic nanoparticle of claim 
1, further comprising a targeting molecule associated with 
the outer polymeric coating. 
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3. The polymer-coated therapeutic nanoparticle of claim 
2, wherein the targeting molecule is covalently bonded to at 
least a portion of the outer polymeric coating. 
4. The polymer-coated therapeutic nanoparticle of claim 
2, wherein the targeting molecule comprises an antibody. 
5. The polymer-coated therapeutic nanoparticle of claim 
2, wherein the targeting molecule comprises a polypeptide. 
6. The polymer-coated therapeutic nanoparticle of claim 
1, wherein the outer polymeric coating comprises a polyes 
ter. 
7. The polymer-coated therapeutic nanoparticle of claim 
1, wherein the outer polymeric coating comprises a biode 
gradable polymer. 
8. The polymer-coated therapeutic nanoparticle of claim 
6, wherein the polyester comprises Poly(e-caprolactone) 
(PCL). 
9. The polymer-coated therapeutic nanoparticle of claim 
1, wherein the inner core is rod-shaped. 
10. The polymer-coated therapeutic nanoparticle of claim 
1, wherein the at least one therapeutic agent comprises an 
anti-cancer agent. 
11. The polymer-coated therapeutic nanoparticle of claim 
1, wherein the maximum dimension of the inner core is 
between 100 nm and 200 nm. 
12. The polymer-coated therapeutic nanoparticle of claim 
1, wherein the outer polymeric coating entirely coats the 
inner core. 
13. The polymer-coated therapeutic nanoparticle of claim 
1, wherein at least a portion of the outer polymeric coating 
is configured to at least partly degrade, thereby releasing the 
at least one therapeutic agent. 
14. A method for producing a polymer-coated therapeutic 
nanoparticle, the method comprising: 
forming an inner core comprising at least one therapeutic 
agent, the inner core having a maximum dimension of 
300 nm or less; 
coating, at least partly, the inner core with a layer of a 
bio-responsive polymer, the layer of the bio-responsive 
polymer having a thickness of 1 nm to 100 nm, and 
attaching at least one targeting molecule to the layer of the 
bio-responsive polymer. 
15. The method of claim 14, wherein the forming the 
inner core and the coating, at least partly, the inner core 
comprises utilizing a solvent diffusion method. 
16. The method of claim 15, wherein the at least one 
therapeutic agent and the bio-responsive polymer are simul 
taneously added to an aqueous solution. 
17. The method of claim 14, wherein the attaching at least 
one targeting molecule comprises covalently bonding the at 
least one targeting molecule to the layer of the bio-respon 
sive polymer. 
18. The method of claim 14, further comprising modify 
ing the layer of the bio-responsive polymer prior to the 
attaching at least one targeting molecule. 
19. A polymer-coated therapeutic nanoparticle compris 
1ng: 
a rod-shaped inner core comprising an anti-cancer thera 
peutic agent, wherein the rod-shaped inner core has a 
maximum dimension of 450 nm or less; 
an outer polymeric coating at least partly covering the 
rod-shaped inner core, wherein the outer polymeric 
coating has a thickness from 1 nm to 100 nm, and 
wherein the outer polymeric coating comprises a bio 
responsive polymer, and 
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at least one targeting molecule covalently attached to the 
outer polymeric coating, wherein the at least one tar 
geting molecule comprises a polypeptide. 
20. The polymer-coated therapeutic nanoparticle of claim 
19, wherein the polypeptide comprises an antibody. 
k k k k k 
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